PET uses specific molecules labelled with positron-emitting radionuclides to provide valuable biochemical and physiological information. However, the administration of radiotracers to patients exposes them to low-dose ionizing radiation, which is a concern in the paediatric population since children are at a higher cancer risk from radiation exposure than adults. Therefore, radiation dosimety calculations for commonly used positron-emitting radiotracers in the paediatric population are highly desired. We evaluate the absorbed dose and effective dose for 19 positron-emitting labelled radiotracers in anthropomorphic paediatric models including the newborn, 1-, 5-, 10-and 15-year-old male and female. This is achieved using pre-calculated S-values of positron-emitting radionuclides of UF-NCI paediatric phantoms and published biokinetic data for various radiotracers. The influence of the type of anthropomorphic model, tissue weight factors and direct human-versus mouse-derived biokinetic data on the effective dose for paediatric phantoms was also evaluated. In the case of 18 F-FDG, dosimetry calculations of reference paediatric patients from various dose regimens were also calculated. Among the considered radiotracers, 18 F-FBPA and 15 O-water resulted in the highest and lowest effective dose in the paediatric phantoms, respectively. The ICRP 103 updated tissue-weighting factors decrease the effective dose in most cases. Substantial differences of radiation dose were observed between direct human-versus mouse-derived biokinetic data. Moreover, the effect of using voxel-versus MIRD-type models on the calculation of the effective dose was also studied. The generated database of absorbed organ dose and effective dose for various positron-emitting labelled radiotracers using new generation computational models and the new ICRP tissue-weighting factors can be used for the assessment of radiation risks to paediatric patients in clinical practice. This work also contributes to a better understanding of the factors influencing patient-specific radiation dose calculation.
Introduction
The noninvasive nature of positron emission tomography (PET) makes it an extremely useful tool for clinical diagnosis, staging, treatment and surveillance of various diseases (Gambhir 2002) . Because of its high sensitivity and target specificity for the paediatric population, PET enables the detection and characterization of disease in its earliest stages and provides valuable diagnostic information that may not be easily obtained using conventional imaging techniques (Tatsumi et al 2007 , Kleis et al 2009 . However, the exposure of paediatric patients to ionizing radiation during standalone or hybrid medical imaging examinations is a matter of concern (Chawla et al 2010 . In this regard, some improved dose regimens and dedicated paediatric PET/CT protocols have been devised and published by various investigators (Accorsi et al 2010 , Jacobs et al 2005 , Gelfand 2010 , Alessio et al 2009 and professional societies (Gelfand et al 2011 , Lassmann et al 2007 .
With the same absolute level of radiation dose, children may experience greater stochastic effects from ionizing radiation than adults because they have a proportionally higher percentage of replicating cells, which are more radiosensitive than other cells (Robbins 2008) . The stochastic effects (e.g. cancer and hereditary effects) are mainly caused by radiation-induced DNA mutation or symmetrical translocations in cells (Mothersill and Seymour 2013, Prasad et al 2004) , and follow a latent period varying from 2 years to 30 years (Steinert et al 2003 , Parker et al 2005 . Since children have longer post-irradiation life period for the emergence of deleterious stochastic effects, they are at higher cancer risk from ionizing radiation compared to adults. In this context, the accurate assessment of radiation dose delivered to the paediatric population involving the use of positron-emitting labelled radiotracers for standalone or hybrid diagnostic imaging techniques (e.g. PET, PET-CT) is of paramount importance in clinical practice.
To this end, organ absorbed doses are often estimated using anthropomorphic computational phantoms and Monte Carlo calculations (Zaidi 1999) . These phantoms and computer codes respectively mimic the morphology and internal anatomic structures of children and simulate the interaction of ionizing radiation with biological tissues, thus allowing tracking the transport of radiation in the human body. Depending on the geometric features used to define the anatomical model for radiation transport calculations, computational models can be divided into three types (Zaidi and Xu 2007) : stylized models which employ simple equation-based mathematical functions, voxel-based models which use matrices obtained from segmented cryosection or medical (CT or MR) images, and hybrid equation-voxel based models which combine the two aforementioned modelling approaches. In most studies reported in the literature (Eberlein et al 2011 , Chawla et al 2010 , the estimation of organ absorbed dose from PET radiotracers to the paediatric population were performed using the dosimetric characteristics of positron-emitting tracers and mathematical paediatric phantoms specified in ICRP publications (ICRP 1988 (ICRP , 1998 (ICRP , 2008 , MIRDOSE (Stabin 1996) or OLINDA (Stabin et al 2005) packages. However, significant differences were reported between dosimetric results of stylized and voxel-based models of the same subject (Petoussi-Henss et al 2007) . To estimate the potential detrimental effects of ionizing radiation, the effective dose is calculated by summing the products of organ absorbed dose and the ICRP recommended tissue-weighting factors. The published reports used the ICRP 60 tissue-weighting factors for effective dose calculation in the paediatric population (ICRP 1988 (ICRP , 1998 (ICRP , 2008 , although new tissue-weighting factors were published in ICRP Publication 103 (Bolch et al 2009) . Differences of 21% to 31% have been reported for the estimates of effective dose between the ICRP 60 and ICRP 103 tissue-weighting factors (Boetticher et al 2008) . Therefore, the assessment of organ absorbed dose and effective dose for commonly used positron-emitting radiotracers in new generation anthropomorphic paediatric phantoms according to the new ICRP tissue-weighting factors is highly desired.
In nuclear medicine, paediatric imaging protocols are usually extrapolated from adult imaging guidelines. The administered radiotracer activity to paediatric patients varies widely on the basis of clinical experience and preference of physicians (Treves et al 2008) . A number of guidelines and methodologies were developed for the calculation of paediatric PET/CT injected activity in an effort to provide guidance on optimal imaging protocols (Gelfand et al 2011 , Accorsi et al 2010 , Lassmann et al 2007 , Alessio et al 2009 , Churchill 1964 , Gelfand 2010 , Du Bois and Du Bois 1916 , 1989 . Since an optimal imaging protocol would result in images with sufficient diagnostic quality at minimum radiation risk (Alessio et al 2011) , it is important to evaluate the dosimetric aspect of different dose regimens in paediatric imaging.
The biokinetic data derived from small animals were used to estimate human radiation dose of new radiotracers. Sakata et al (2013) reported significant discrepancy between direct human-and mouse-derived organ doses and effective dose for adults. However, the direct comparison of animal-and human-derived radiation dose for the paediatric population has not been reported so far.
In this work, human biodistribution data of 19 positron-emitting labelled radiotracers were obtained from published literature (ICRP 1988 , 1998 , 2008 , Sakata et al 2013 . Organ absorbed doses and effective dose were calculated using these biokinetic data, Monte Carlo calculated S-values of positron-emitting radionuclides of the University of Florida-National Cancer Institute (UF-NCI) family of paediatric models, and the ICRP 103 tissue-weighting factors. The obtained radiation dose database can be used to assess the deterministic and stochastic effects to children undergoing PET imaging procedures at different ages. The dosimetric properties of different dose regimens for 18 F-FDG, taken as an example as the most widely used tracer, were also calculated for the paediatric phantoms used in this work. A detailed knowledge of the influence of the type of anthropomorphic model, tissue-weight factor, dose regimen and human/mouse-derived biokinetic data on the effective dose to the paediatric population may advance the understanding of the uncertainties involved in internal radiation dosimetry calculations.
Materials and methods

Radiotracers
The radiotracers investigated in this work are 18 F-FDG (Reivich et al 1985) , 11 C-acetate (Visser 2001 , Albrecht et al 2007 , 11 C-and 18 F-amino acids, 11 C-methionine (Huang and McConathy 2013) , 11 C-and 18 F-brain receptor substances (ICRP 2008) , 11 C-thymidine, [Methyl- 11 C]-thymidine (Goethals et al 1996) , 11 C-SA4503 (Toyohara et al 2009) , 11 C-MPDX (Sakata et al 2013) . The list abbreviations (radiotracers, organs, quantities) used in this work are summarized in table 1. The application, source organs containing high activity concentration and the sources of the biodistribution data of the various radiotracers used in this work are listed in table 2.
Definition of organs and tissues for dose calculation
The UF-NCI hybrid paediatric phantom series, including the reference newborn, 1-, 5-, 10-, and 15-year-old male and female models, were used for radiation dosimetry calculations. Figure 1 shows the front 3D views of the ten paediatric phantoms used in this work. For the sake of convenience in terms of effective dose calculation, homogeneous organs such as the left lung and right lung, the submaxillary salivary gland and sublingual salivary gland, the cartilage, cortical bone and spongiosa at different bone sites were merged as one identified region. The body weights and organ/tissue masses for the paediatric phantoms are summarized in the supplemental table A1 (available from stacks.iop.org/PMB/59/1165/mmedia).
The Monte Carlo N-Particle eXtended code (version 2.5.c) was adopted for radiation transport simulation of positron-emitting sources in the UF-NCI paediatric phantoms. The decay data of the investigated positron-emitting radionuclides were obtained from the Health Physics Society electronic resource (HPS 2013). The energy deposited by photons, electrons, and positrons in organs/tissues were recorded in unit of MeV per particle. An in-house C++ code was developed to calculate the absorbed doses and effective doses in paediatric models for the considered radiotracers using published biokinetic data, currently available (Goethals et al 1996) 11 C-Thymidine Cell proliferation in malignant x Liver, blood, kidney tumours (Goethals et al 1996) 11 C-SA4503 Sigma1 receptor (Toyohara x Brain, heart wall, liver, lung, pancreas, et al 2009) spleen, thyroid, kidney, SI, stomach, UB 11 C-MPDX Adenosine A1 receptor (Paul x Brain, heart wall, liver, lung, thyroid, et al 2011) kidney, SI, stomach, UB 11 C-TMSX Adenosine A2A receptor x Brain, heart wall, liver, lung, thyroid, (Mishina et al 2011) GB, kidney, SI, stomach, UB 11 C-CHIBA-1001 DNA synthesis (Toyohara x Brain, heart wall, liver, lung, pancreas, et al 2011) spleen, thyroid, GB, kidney, SI, stomach, UB tissue weight factors and the recently evaluated S-values of C-11, F-18, O-15 and Ga-68 (Xie et al 2013) . The absorbed dose is calculated for 59 target organs/tissues by performing the sum of contributions from radioactive decay occurring in various source organs/tissues. The radiotracer is assumed to be uniformly distributed in the source regions. For source organs without specified biokinetic data, the accumulated activity for radiotracers is determined by multiplying the volume fraction and the accumulated activity quoted for 'other organs and tissues'. The absorbed dose to red bone marrow is approximated by the absorbed dose to spongiosa for effective dose calculation. The absorbed dose to blood vessels refers to the dose to the blood in the arteries and the veins. The absorbed doses to the colon, gall bladder (GB), heart, small intestine (SI), stomach, urinary bladder (UB), kidney (total) and skeleton (total) refer to the mean absorbed dose for the integrated organ, including the wall and content for colon, GB, heart, SI, stomach, and UB, the cortex, medulla and pelvis for the kidney, and the cortical bone, spongiosa and cartilage for the skeleton. Age-dependent organ mass, biokinetic data and S-values were used for the absorbed dose calculation. For all organs except the UB content, the biokinetic data and accumulated activity of radiotracers are similar for adults and children of different ages. For UB content, the accumulated activity of 11 C-and 18 F-brain receptor substances, 18 F-L-DOPA, 18 F-FDG, 18 F-amino acids and 68 Ga-EDTA vary according to the considered paediatric population model. Since the newborn is traditionally considered to empty its bladder automatically (Sillen 2001) , the activity concentration of these radiotracers in the UB content is assumed to be identical to 'other organs and tissues'.
Absorbed dose and effective dose calculations
In radiation biology, clinical radiology, and radiological protection the absorbed dose is the basic physical dose quantity defined as the mean energy imparted to target tissue per unit tissue mass. In the Medical Internal Radiation Dose (MIRD) formalism (Bolch et al 2009) , the radiation absorbed dose D (r T , T D ) delivered to any target tissue r T from source organ r S , over a considered dose-integration period T D is calculated according to equation (A.1) (see the appendix). The S-value describes the equivalent dose rate in the target organ per unit activity in the source organ and depends on the decay scheme of the radionuclide, the type, energy and yield of emitted radiation per nuclear transformation, the mass of the target organ, and the pre-constructed age-and sex-specific anatomical model. In this work, the S-values of the considered reference paediatric phantoms for C-11, O-15, F-18 and Ga-68 (Xie et al 2013) were employed for absorbed dose calculations.
The detriment caused by radiation to the human body depends on the linear energy transfer of the different types of radiation emitted by the radionuclide. To relate the absorbed dose to stochastic effects, the absorbed dose in organs/tissues is multiplied by the radiation weighting factor and the result is termed the equivalent dose,
To reflect the combined detriment from stochastic effects of equivalent doses in all organs/tissues of the human body, the concept of effective dose was introduced by ICRP (1991 ICRP ( , 2007 , and is calculated by the sum of the product of tissue-weighting factor (ω T ) and equivalent doses (equation (A.3) ). The values of ω T describe the relative contribution of individual organs/tissues to the overall radiation detriment, thus T ω T = 1. The tissueweighting factors for organs/tissues given by the ICRP Publication 60 (ICRP 1991) and ICRP Publication 103 (ICRP 2007) are summarized in table 3. It should be noted that the ω T values represent mean values for humans averaged over both sexes and all ages.
If A(r S , t ) is normalized to a unit administered activity A 0 , then the absorbed dose to the target tissue and the effective dose in the human body per unit administered activity can be obtained from equations (A.4) and (A.5), respectively.
For the purpose of radiological protection, the ICRP (ICRP 2007) suggests to apply a single value of effective dose for both sexes. The sex-specific equivalent doses are then averaged resulting in equivalent doses of a reference person. The sex-averaged equivalent doses of the reference person are then weighted by the tissue-weighting factors and summed over all organs and tissues for the assessment of the effective dose according to equation (A.6). 
Results
Absorbed dose and effective dose
The absorbed dose to 59 target organs from the 19 investigated radiotracers was calculated in the considered paediatric phantoms. The organ absorbed doses for these radiotracers are provided in supplemental tables A2-A20 (available from stacks.iop.org/PMB/59/1165/mmedia). The highest absorbed dose to critical organs can be observed in the UB wall for 11 C-methionine, 11 C (realistic maximum model), 11 C-4DST and 18 F-FBPA; the kidney and UB wall for 18 F-Ldopa and 68 Ga-EDTA; the pancreas for 11 C-and 18 F-amino acids; the kidney for 11 C-acetate and 11 C-thymidine; the liver for [Methyl-11 C]-thymidine and 11 C-MPDX; the UB wall and GB wall for 11 C-brain receptor substances; the liver, spleen, thyroid and testes for 15 O-water; the GB wall, stomach wall and thyroid for 18 F-brain receptor substances; the heart wall for 18 F-FDG; the spleen and thyroid for 11 C-SA4503; the GB wall for 11 C-TMSX; and the SI wall and stomach wall for 11 C-CHIBA-1001, respectively. Figure 2 shows the absorbed doses from different radiotracers for the kidney (total), lung, UB wall and breast for the newborn, 1-, 5-, 10-and 15-year-old female models. For most radiotracers, the organ absorbed dose per unit administered activity decreases when the body weight increases. However, for 11 C-and 18 F-brain receptor substances, 18 F-L-DOPA, 18 F-FDG, 18 F-amino acids and 68 Ga-EDTA, the absorbed dose to the UB wall is lower in the newborn than in the 1-year-old child because these radiotracers present with high activity concentration in the UB content and the bladder of the newborn has higher voiding frequency than children at other ages. Among all considered radiotracers, 15 O-water produces the lowest absorbed dose to all organs because of the short half-life of the radionuclide (2 min), in contrast to the relatively longer half-lives of F-18 and Ga-68 (110 and 68 min), respectively. Figure 3 shows the absorbed dose per unit administered activity of representative radiotracers to critical organs of the 15-year female model. For organs except kidney, liver and UB wall, the mean absorbed dose of F-18 and Ga-68 labelled radiotracers would be 3.3-5.5 times higher than C-11 labelled radiotracers, and 7.2-21.1 times higher than the absorbed dose from 15 O-water. The effective dose per unit administered activity of 19 radiotracers in the newborn, 1-, 5-, 10-and 15-year-old models calculated using tissue-weighting factors of the ICRP 103 are summarized in table 4. Among the considered radiotracers and paediatric patients at varying ages, 18 F-FBPA produces the highest effective dose ranging from 3.37E−02 to 3.43E−01 mSv/MBq while 15 O-water produces the lowest effective dose ranging from 1.24E−03 to 1.39E−02 mSv/MBq.
68 Ga-EDTA, as an agent for renal function investigation, delivers a high absorbed dose to the urinary system (kidney and UB) and results in a high effective dose ranging from 3.20E−02 to 1.59E−01 mSv/MBq.
Dosimetric results from different models
On the basis of the same biokinetic data, we compared the calculated organ absorbed dose and effective dose in the voxel-based paediatric models with the dosimetric estimates published in the ICRP 106 where stylized paediatric phantoms were used. Figure 4 shows the Bland-Altman plots comparing dose estimates to target organs of the 1-, 5-10-and 15-year-old UF-NCI and Ga-EDTA). The average percentage differences between organ absorbed doses between the two family of phantoms are 4.3 ± 22.6% with a 95% confidence interval (CI) of (−40%, 48.5%) for 11 C-acetate, 4.1 ± 47.6% with a 95% CI of (−89.1%, 97.3%) for 15 O-water, 0.2 ± 25.8% with a 95% CI of (−50.4%, 50.8%) for 18 F-FDG, and −8.4 ± 32% with a 95% CI of (−71.1%, 54.3%) for 68 Ga-EDTA, respectively. The absorbed dose differences were outside the limits of agreement in six cases (6.3% of all cases) of spleen, pancreas and cortical bone for 11 C-acetate, nine cases (9.4% of all cases) of testes, cortical bone and bone marrow for 15 O-water, in nine cases (9.4% of all cases) of uterus, ovaries and bladder for 18 F-FDG, and in ten cases (10.4% of all cases) of uterus, ovaries, lung and bladder for 68 Ga-EDTA. Organ absorbed dose differences were equally distributed and unbiased across the mean dose range for 11 C-acetate and 18 F-FDG, while the percentage difference presented a positive correlation to the magnitude of organ absorbed dose for 15 O-water. Organs absorbed dose of ICRP 106 at 64.5% of the data points for 68 Ga-EDTA is lower than those of the UF-NCI phantoms. Ga-EDTA of the newborn, 1-year, 5-year, 10-year and 15-year paediatric phantoms. Figure 5 shows the calculated effective dose to the UF-NCI phantoms using ICRP 60 weighting factors and kinetic data provided in the ICRP 106 for representative radiotracers. The effective dose of ICRP 106 for most paediatric models at different ages is slightly higher than that of UF-NCI phantoms. The relative differences of the effective dose between stylized and voxel-based phantoms are −22.2 ± 1.9%, 1.8 ± 13.3%, −11.0 ± 2.3%, and −16.8 ± 16.1% for 11 C-Acetate, 15 O-Water, 18 F-FDG and 68 Ga-EDTA, respectively.
Influence of ICRP103 dosimetry schema on effective dose calculation
Figure 6 compares effective doses in the UF-NCI paediatric phantoms for the 19 considered positron-emitting labelled radiotracers using the same biokinetic data and tissue-weighting factors of the ICRP 60 and ICRP 103, respectively. As shown in figure 6(a), for 11 CAcetate, the new ω T of the ICRP 103 increases the effective dose to the paediatric models by 9.6%. For 11 C-thymidine, 11 C-SA4503, 11 C-MPDX, 11 C-TMSX and 11 C-CHIBA-1001, the effective doses calculated using weighting factors of the ICRP 103 are about 2.5% lower than those calculated using the ICRP 60 factors at all ages. For other radiotracers, the ratios of the effective doses obtained using ICRP 60 to ICRP 103 vary between 0.96 and 1.36, where the new ω T of ICRP 103 generate lower effective doses than the old ω T of the ICRP 60 in all paediatric phantoms, except for the newborn. The Bland-Altman analysis ( figure 6(b) ) demonstrates a good agreement between the effective doses for 19 radiotracers when using the weighting factors recommended in both ICRP reports. The mean relative difference between effective doses from ICRP 60 to ICRP 103 tissue-weighting factors is 7.3 ± 9.1% with a 95% CI of (−10.7%, 25.2%). The mean relative difference of effective doses between the two recommended tissue-weighting factors for all studied radiotracers are 2.9 ± 6.6%, 8.3 ± 8.8%, 8.9 ± 10.2%, 10.9 ± 12.1% and 9.0 ± 11.1% for the newborn, 1-, 5-10-and 15-year-old paediatric models, respectively. Accorsi et al (2010) . c Accorsi et al (2010 ), Churchill (1964 . d The BSA is calculated using the body surface area formula of Du Bois et al (Gelfand 2010 , Gelfand et al 2011 , Du Bois and Du Bois 1916 , 1989 ). e Gelfand et al (2011) , Accorsi et al (2010) .
3.4.
F-FDG radiation dose from different regimens
Seven
18 F-FDG-PET dose regimens used in different facilities and reported in recent publications (table 5) were used to estimate the injected activity of 18 F-FDG for the reference paediatric patients of different ages where the reference activity for adults is assumed to be 370 MBq according to protocols used in our institution. Figure 7 (a) presents the recommended administered activity of 18 F-FDG for children when using different dosing strategies whereas figure 7(b) compares the resulting effective doses to the female models. In 18 F-FDG imaging, the effective dose for paediatric patients may vary from 1.7 to 9.4 mSv when using the different dose regimens. For 1-, 5-and 10-year-old reference paediatric models, the lowest effective dose is produced by the dose regimen suggested by Accorsi et al (2010) (2.0, 1.7 and 2.1 mSv, respectively). For the newborn, the minimum level of the North American consensus guideline and EANM dose card generate the lowest and second lowest effective dose (2.3 and 2.5 mSv, respectively) whereas the EANM dose card produces the lowest effective dose to the 15-year-old model (3.4 mSv). In the 18 F-FDG PET scans, the source organs containing high activity concentration include UB content, heart wall, brain, liver and the lungs. Figure 8 shows the absorbed dose to the heart wall and UB wall for 18 F-FDG when using different dosing strategies. Similar to the effective dose, the absorbed dose to the heart wall and UB wall of the different paediatric phantoms vary from 7.4 to 48.5 mGy and from 1.9 to 24.7 mGy, respectively for the various dose regimens.
3.5. Effect of human/mouse-derived biokinetic data on paediatric dosimetry Figure 9 compares human/mouse-derived organ absorbed dose and effective dose for the paediatric models at different ages for some radiotracers ( 11 C-SA4503, 11 C-MPDX, 11 C-TMSX, 11 C-CHIBA-1001, 11 C-4DST and 18 F-FBPA). Figure 9 (a) shows the Bland-Altman plots comparing human/mouse-derived organ absorbed doses for the different anatomical models. The mean relative difference between organ absorbed doses resulting from the use of human-to mouse-derived calculations is 5.5 ± 44.4% with a 95% CI of (−81.7%, 92.6%). The absolute difference for 18.1% of the data points is higher than 50%. The ratios between human-and mouse-derived effective doses for the paediatric phantoms are shown in figure 9(b) . The mean ratios for 11 C-SA4503, 11 C-MPDX, 
Discussion
The development of novel molecular PET imaging probes produced by labelling biological molecules with positron-emitting radionuclides is an active research field (Valliant 2010) . Accurate dosimetry calculations for representative groups of paediatric patients is needed to optimize the dose regimens of various radiotracers and to investigate the collective radiation exposure and risks associated with nuclear medicine procedures. In this work, we estimated organ absorbed dose and effective dose using new generation of reference age and sexdependent computational paediatric phantoms and the latest dosimetric data available for 19 positron-emitting labelled radiotracers. For the evaluated radiotracers, the organ absorbed dose may vary from 2.68 × 10 −4 to 12.9 mGy/MBq depending on the physical half-life of the radionuclide and the biological half-life and biodistribution of the radiotracer. In general, F-18 and Ga-68 labelled radiotracers produce a higher absorbed dose in most organs and result in higher effective dose for paediatric patients compared to C-11 and O-15 labelled radiotracers, because of the longer physical half-life.
We studied the effect of the type of anthropomorphic model, dosimetric and biokinetic data and dose regimens on internal radiation dose calculations from various radiotracers to the paediatric population. A large difference is observed for some organ absorbed dose between the MIRD-type and the voxel-based phantoms. The absolute difference for about 34% of organs is higher than 20%, especially, for spleen, pancreas, uterus, cortical bone, bone marrow, gonads, lung and bladder. The absorbed dose difference is out of the 95% CI for some radiotracers and some organs. The MIRD-type phantom overestimates the effective dose by 6.8%-39% compared to its voxel-based model counterpart in most paediatric phantoms for the selected radiotracers. The ICRP publication 103 (ICRP 2007) proposed new tissue-weighting factors for the calculation of the effective dose for radiation protection purposes where the breast weighting factor increased from 0.05 to 0.12. For anterior-posterior geometry in external radiation exposure, the new ICRP 103 ω T produces moderate impact on the effective dose for photon energies below 0.1 MeV and electron energies between 1 and 4 MeV (ICRP 2010). The effect is definitely energy-and geometry-dependent and there are energies and geometries for which effective doses according to ICRP 103 are higher than those of ICRP 60 and vice versa (Boetticher et al 2008) . However, in internal radiation dosimetry, the breast is not the critical organ and as such, the change of the breast weighting factor plays a minor role in the calculation of the effective dose for PET radiotracers. As shown in table 3, the gonads (ovaries and testes) weighting factors decreased significantly from 0.2 in ICRP 60 to 0.08 in ICRP 103. Accordingly, the effective dose reduced the overall contribution of the gonads dose to the total dose. The gonads dose depends on the cumulated activity of radiotracers in the ovaries/testes for self-irradiation and in adjacent organs, such as the UB, for crossirradiation. The increased tissue-weighting factors for critical organs, such as the heart wall and kidneys explains the increase of the effective dose. For 11 C-acetate, the gonads and UB have low activity concentration whereas the heart wall and kidney have significantly high activity than other organs. The effective dose calculated using ICRP 103 weighting factors is about 10% higher than the one obtained using ICRP 60. For radiotracers such as 18 F-FBPA, the highest cumulated activity is present in the UB of all organs. The effective dose using the new ω T decreased by about 14%. In this work, the bladder of the newborn was assumed to have high voiding frequency, which results in a low cumulated activity for the UB and low cross-absorbed dose to the gonads of the newborn. Therefore, the newborn's effective dose for most radiotracers is less influenced by changes in ω T compared to other paediatric models.
A variety of dose regimens were proposed to determine the optimal injected activity for paediatric patients. Popular dose regimens can be roughly classified into five classes: weightbased rules, such as Clark's formula (Accorsi et al 2010 , Churchill 1964 , the North American consensus guideline (Gelfand et al 2011) ; body surface area-based rule (Gelfand 2010 , Gelfand et al 2011 , Du Bois and Du Bois 1916 , 1989 ; age-based rule (Gelfand et al 2011 , Accorsi et al 2010 ; the dose cards of the EANM (Lassmann et al 2007) and weight category-based dose card proposed by Alessio et al (2009) ; and the patient-specific noise-equivalent count rate density method developed by Accorsi et al (2010) . In the North American consensus guideline for 18 F-FDG, the low end of the dose range should be considered for smaller patients, and the administered activity may take into account patient's weight and time available on the PET scanner. Different dose regimens would result in significantly different levels of injected activity and thus effective dose for the paediatric population. In the case of 18 F-FDG and the newborn as model, Webster's formula produces the highest effective dose, which is about three times higher than the effective dose produced by the EANM dose card. Overall, the minimum level of the North American consensus guideline generates the lowest effective dose in the newborn. The dose regimen proposed by Accorsi et al produced the lowest effective dose for 1-, 5-and 10-year-old models, whereas the EANM dose card produced the lowest and secondary lowest effective dose for 15-year-old and the newborn models, respectively. In this context, the dose regimen of Accorsi et al and the EANM dose card produce the lowest effective doses compared to other dose regimens for the reference paediatric models.
The use of human-versus and mouse-derived biokinetic data result in noticeable discrepancy between organ absorbed dose and effective dose estimates for the paediatric population. The absorbed dose and effective dose differences vary from −115.6% to 170.2% and from −29.5% to 99.5%, respectively. Similar to observations made for adults, the use of mouse-derived biokinetic data is often not satisfactory enough for assessing the absorbed dose distributions and radiation risks in paediatric radiation dosimetry. Consequently, biodistribution and biokinetic studies in humans are required for most novel molecular imaging probes.
Conclusion
A methodical study was conducted to evaluate the radiation dose from positron-emitting labelled radiotracers to the paediatric population using the latest generation anthropomorphic computational phantoms and updated tissue-weighting factors. We also investigated the impact of different types of anthropomorphic models, tissue-weighting factors, dose regimens and biokinetic data on the resulting organ absorbed dose and effective dose. Model-specific differences of the effective dose were observed on paediatric phantoms at different age for most radiotracers. For most radiotracers with low activity concentration in the breast, the implementation of ICRP 103 tissue-weighting factors decreases the estimated effective dose to paediatric patients. The various dose regimens provide different levels of injected activity and as such result in high effective dose to some cases. The choice of a suitable dose regimen in clinical practice will significantly reduce the radiation risks for paediatric patients. The calculation of the effective dose strongly depends on the biodistribution and biokinetic data of radiotracers. Consequently, human-based biokinetic studies are often desired for most new PET imaging probes. The generated database of organ absorbed dose and effective dose for various positron-emitting labelled radiotracers can be used to assess the radiation risks to the paediatric population in clinical PET imaging procedures.
The effective dose E is given by
where ω T is the tissue-weighting factor for organ/tissue T reflecting its relative radiation sensitivity.
The absorbed dose to the target tissue per unit administered activity is given by
The effective dose in the human body per unit administered activity is given bỹ
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